Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

28 Aug 2018 Results published in the Journal of Infectious Diseases.
24 Mar 2016 Primary end points has been modified.
16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com